Candriam S.C.A. Eagle Pharmaceuticals, Inc. Transaction History

Candriam S.C.A.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2019 Oct 21, 2019	SELL	$53.25 - $59.98 $852,000 - $959,680	-16,000 Closed	0 $0
Q2 2019 Aug 01, 2019	SELL	$46.61 - $58.45 $372,880 - $467,600	-8,000 Reduced 33.33%	16,000 $887,000
Q4 2017 Feb 07, 2018	SELL	$49.6 - $60.87 $1.74 Million - $2.13 Million	-35,000 Reduced 59.32%	24,000 $1.28 Million
Q3 2017 Nov 03, 2017	BUY	$46.62 - $60.36 $2.75 Million - $3.56 Million	59,000	59,000 $3.52 Million

8.6M

100

Ticker EGRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 13,015,900
Market Cap $7.81M
Description
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and in...

Get notified when there are updates to the investment portfolio of Candriam S.C.A., based on Form 13F filings with the SEC.

Stay updated on Candriam S.C.A. with notifications on news.